Lagoda Investment Management Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Clorox
CLX
|
+$8.36M |
| 2 |
XEC
CIMAREX ENERGY CO
XEC
|
+$1.04M |
| 3 |
NVO
Novo Nordisk
NVO
|
+$510K |
| 4 |
XPO
XPO
|
+$367K |
| 5 |
Precigen
PGEN
|
+$253K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TTOO
T2 Biosystems, Inc
TTOO
|
+$7.39M |
| 2 |
Berkshire Hathaway Class B
BRK.B
|
+$6.13M |
| 3 |
Johnson & Johnson
JNJ
|
+$4.78M |
| 4 |
Tesla
TSLA
|
+$2.93M |
| 5 |
VolitionRx Ltd
VNRX
|
+$2.68M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 24.11% |
| 2 | Financials | 15.66% |
| 3 | Consumer Discretionary | 12.78% |
| 4 | Energy | 11.73% |
| 5 | Technology | 10.25% |
Similar funds
Lagoda Investment Management's Q3 2018 Portfolio in Review
As of Q3 2018, Lagoda Investment Management held 37 positions worth $239M, down 0.62% from $241M the previous quarter. Its ten largest holdings account for 71% of the portfolio.
Lagoda Investment Management withdrew a net $23M in Q3 2018, closing 2 positions and reducing 21 holdings. Its most notable exit was T2 Biosystems, Inc, an estimated $7.39M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 24% of assets, down from 25% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Lagoda Investment Management added an estimated $8.36M to Clorox.
- Lagoda Investment Management added most to Clorox in Q3 2018, an estimated $8.36M increase.
- Lagoda Investment Management's biggest Q3 2018 reduction was Berkshire Hathaway Class B, cutting an estimated $6.13M.
- Lagoda Investment Management fully exited T2 Biosystems, Inc in Q3 2018, selling an estimated $7.39M.
- Lagoda Investment Management's ten largest holdings make up 71% of its $239M portfolio in Q3 2018.
- Lagoda Investment Management opened 0 new positions and closed 2 in Q3 2018.
- Lagoda Investment Management's portfolio value fell 0.62% quarter-over-quarter to $239M.
Based on Lagoda Investment Management's 13F filing for Q3 2018, filed 14 Nov 2018.